title: Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion.
abstract: Cessation of drug use in chronic opiate abusers produces a severe withdrawal syndrome that is highly aversive, and avoidance of withdrawal or associated stimuli is a major factor contributing to opiate abuse. Increased noradrenaline in the brain has long been implicated in opiate withdrawal, but it has not been clear which noradrenergic systems are involved. Here we show that microinjection of beta-noradrenergic-receptor antagonists, or of an alpha2-receptor agonist, into the bed nucleus of the stria terminalis (BNST) in rats markedly attenuates opiate-withdrawal-induced conditioned place aversion. Immunohistochemical studies revealed that numerous BNST-projecting cells in the A1 and A2 noradrenergic cell groups of the caudal medulla were activated during withdrawal. Lesion of these ascending medullary projections also greatly reduced opiate-withdrawal-induced place aversion, whereas lesion of locus coeruleus noradrenergic projections had no effect on opiate-withdrawal behaviour. We conclude that noradrenergic inputs to the BNST from the caudal medulla are critically involved in the aversiveness of opiate withdrawal.
authors.affiliation: University of Pennsylvania School of Medicine, Department of Psychiatry, VA Medical Center, Philadelphia 19104, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Delfs
authors.forename: Y
authors.initials: Y
authors.lastname: Zhu
authors.forename: J P
authors.initials: JP
authors.lastname: Druhan
authors.forename: G
authors.initials: G
authors.lastname: Aston-Jones
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000679:Amygdala / Q000187:drug effects / Q000502:physiology; D000818:Animals; D015784:Betaxolol / Q000494:pharmacology; D003000:Clonidine / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D009294:Narcotics / Q000009:adverse effects*; D009475:Neurons, Afferent / Q000378:metabolism / Q000502:physiology; D009638:Norepinephrine / Q000502:physiology*; D011412:Propanolamines / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D016548:Prosencephalon / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D009294:Narcotics; D011412:Propanolamines; C026777:ICI 118551; C011266:ST 91; D011433:Propranolol; D014446:Tyrosine 3-Monooxygenase; D003000:Clonidine; D015784:Betaxolol; D009638:Norepinephrine